

LONDON, Feb 11 (Reuters) - Shire, the London-listed drugmaker buying Baxalta International for $32 billion, reported a better-than-expected 13 percent...


(ShareCast News) - Shire beat fourth quarter sales forecasts and issued much stronger guidance for 2016, targeting double digit top-line growth and a ...


(ShareCast News) - RBC Capital Markets upgraded Shire to 'outperform' from 'sector perform', keeping the $240 price target ahead of the company's four...


(ShareCast News) - Specialty biopharmaceutical company Shire said David Kappler will step down as deputy chairman and senior independent director. Mea...


(ShareCast News) - RBC Capital Markets upgraded Shire to 'outperform' from 'sector perform', keeping the $240 price target ahead of the company's four...